Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2017 Feb 11;389(10069):603-611.
doi: 10.1016/S0140-6736(16)32410-2. Epub 2017 Jan 10.

Thrombolytic removal of intraventricular haemorrhage in treatment of severe stroke: results of the randomised, multicentre, multiregion, placebo-controlled CLEAR III trial

Daniel F Hanley  1 , Karen Lane  2 , Nichol McBee  2 , Wendy Ziai  2 , Stanley Tuhrim  3 , Kennedy R Lees  4 , Jesse Dawson  4 , Dheeraj Gandhi  5 , Natalie Ullman  2 , W Andrew Mould  2 , Steven W Mayo  6 , A David Mendelow  7 , Barbara Gregson  7 , Kenneth Butcher  8 , Paul Vespa  9 , David W Wright  10 , Carlos S Kase  11 , J Ricardo Carhuapoma  2 , Penelope M Keyl  2 , Marie Diener-West  12 , John Muschelli  12 , Joshua F Betz  12 , Carol B Thompson  12 , Elizabeth A Sugar  12 , Gayane Yenokyan  12 , Scott Janis  13 , Sayona John  14 , Sagi Harnof  15 , George A Lopez  16 , E Francois Aldrich  5 , Mark R Harrigan  17 , Safdar Ansari  18 , Jack Jallo  19 , Jean-Louis Caron  20 , David LeDoux  21 , Opeolu Adeoye  22 , Mario Zuccarello  22 , Harold P Adams Jr  23 , Michael Rosenblum  12 , Richard E Thompson  12 , Issam A Awad  24 ; CLEAR III Investigators
Affiliations
Clinical Trial

Thrombolytic removal of intraventricular haemorrhage in treatment of severe stroke: results of the randomised, multicentre, multiregion, placebo-controlled CLEAR III trial

Daniel F Hanley et al. Lancet. .

Abstract

Background: Intraventricular haemorrhage is a subtype of intracerebral haemorrhage, with 50% mortality and serious disability for survivors. We aimed to test whether attempting to remove intraventricular haemorrhage with alteplase versus saline irrigation improved functional outcome.

Methods: In this randomised, double-blinded, placebo-controlled, multiregional trial (CLEAR III), participants with a routinely placed extraventricular drain, in the intensive care unit with stable, non-traumatic intracerebral haemorrhage volume less than 30 mL, intraventricular haemorrhage obstructing the 3rd or 4th ventricles, and no underlying pathology were adaptively randomly assigned (1:1), via a web-based system to receive up to 12 doses, 8 h apart of 1 mg of alteplase or 0·9% saline via the extraventricular drain. The treating physician, clinical research staff, and participants were masked to treatment assignment. CT scans were obtained every 24 h throughout dosing. The primary efficacy outcome was good functional outcome, defined as a modified Rankin Scale score (mRS) of 3 or less at 180 days per central adjudication by blinded evaluators. This study is registered with ClinicalTrials.gov, NCT00784134.

Findings: Between Sept 18, 2009, and Jan 13, 2015, 500 patients were randomised: 249 to the alteplase group and 251 to the saline group. 180-day follow-up data were available for analysis from 246 of 249 participants in the alteplase group and 245 of 251 participants in the placebo group. The primary efficacy outcome was similar in each group (good outcome in alteplase group 48% vs saline 45%; risk ratio [RR] 1·06 [95% CI 0·88-1·28; p=0·554]). A difference of 3·5% (RR 1·08 [95% CI 0·90-1·29], p=0·420) was found after adjustment for intraventricular haemorrhage size and thalamic intracerebral haemorrhage. At 180 days, the treatment group had lower case fatality (46 [18%] vs saline 73 [29%], hazard ratio 0·60 [95% CI 0·41-0·86], p=0·006), but a greater proportion with mRS 5 (42 [17%] vs 21 [9%]; RR 1·99 [95% CI 1·22-3·26], p=0·007). Ventriculitis (17 [7%] alteplase vs 31 [12%] saline; RR 0·55 [95% CI 0·31-0·97], p=0·048) and serious adverse events (114 [46%] alteplase vs 151 [60%] saline; RR 0·76 [95% CI 0·64-0·90], p=0·002) were less frequent with alteplase treatment. Symptomatic bleeding (six [2%] in the alteplase group vs five [2%] in the saline group; RR 1·21 [95% CI 0·37-3·91], p=0·771) was similar.

Interpretation: In patients with intraventricular haemorrhage and a routine extraventricular drain, irrigation with alteplase did not substantially improve functional outcomes at the mRS 3 cutoff compared with irrigation with saline. Protocol-based use of alteplase with extraventricular drain seems safe. Future investigation is needed to determine whether a greater frequency of complete intraventricular haemorrhage removal via alteplase produces gains in functional status.

Funding: National Institute of Neurological Disorders and Stroke.

PubMed Disclaimer

Figures

Figure 1:
Figure 1:. Trial profile
In the alteplase group, one participant who was initially thought to be lost to follow-up at day 30 was located and assessed at day 180.
Figure 2:
Figure 2:. Outcome dichotomies of mRS (left panel; scores range from 0 [no disability] to 6 [death]) and eGOS (right panel; scores range from 8 [upper good recovery] to 1 [death]) scores at 30 days and 180 days by treatment
The left panel blue lines indicate the differences in proportion of 180 day mRS ≤3 (112 [45%] in the saline group vs 118 [48%] in the alteplase group; p=0·477) and deceased participants (73 [30%] in the saline group vs 46 [19%] in the alteplase group; p=0O04). mRS=modified Rankin Scale. eGOS=extended Glasgow Outcome Scale. GR=good recovery. MD=moderate disability. SD=severe disability. VS=vegetative state.
Figure 3:
Figure 3:. Kaplan-Meier survival estimates from day of randomisation to observed day of death with truncation at 193 days for late and missed 180-day visits (n=36), which corresponds to the longest in-window 180-day visit
Estimated survival probabilities were higher throughout 180 days of follow-up with alteplase compared with saline (p=0·006). Shading shows 95% CI.
Figure 4:
Figure 4:. Subgroup analysis
Forest plot of interaction terms, adjusted for age, sex, thalamic intracerebral haemorrhage location, stability intracerebral haemorrhage, intraventricular haemorrhage volume, and GCS (mild, 13–15; moderate, 9–12; severe, 3–8) at admission. The size of points indicates the relative sizes of the subgroups. Scores on the Glasgow Coma Scale (GCS) range from 15 (fully conscious) to 3 (deep coma). sIVH=stability intraventricular haemorrhage volume. ICH=intracerebral haemorrhage. Rnd Sx=randomised after symptom onset.
See this image and copyright information in PMC

Comment in

References

    1. Hanley DF. Intraventricular hemorrhage severity factor and treatment target in spontaneous intracerebral hemorrhage. Stroke 2009; 40: 1533–38. - PMC - PubMed
    1. Hansen BM, Morgan TC, Betz J, et al. Intraventricular extension of supratentorial intracerebral hemorrhage: the modified graeb scale improves outcome prediction in lund stroke register. Neuroepidemiology 2015; 46: 43–50. - PMC - PubMed
    1. Tuhrim S, Horowitz DR, Sacher M, Godbold JH. Volume of ventricular blood is an important determinant of outcome in supratentorial intracerebral hemorrhage. Critical Care Med 1999; 27: 617–21. - PubMed
    1. Qureshi AI, Tuhrim S, Broderick JP, Batjer HH, Hondo H, Hanley DF. Spontaneous intracerebral hemorrhage. New Engl J Med 2001; 344: 1450–60. - PubMed
    1. Moradiya Y, Murthy SB, Newman-Toker DE, Hanley DF, Ziai WC. Intraventricular thrombolysis in intracerebral hemorrhage requiring ventriculostomy a decade-long real-world experience. Stroke 2014; 45: 2629–35. - PMC - PubMed

Publication types

Associated data